Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | F7 | P08709 | 2/20 | 0.53 |
| ▸ | F3 | P13726 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.53 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17107448 | 0.93 | LPAR2 (0.57) | ALDH1A1F7F3MAPTCYP19A1 | |
| SCHEMBL13491427 | 0.92 | ALDH1A1 (0.53) | ALDH1A1F7F3MAPTCYP19A1 | |
| Sulfuric Acid SCHEMBL17956299 | 0.89 | ALDH1A1 (0.53) | ALDH1A1F7F3MAPTCYP19A1 | |
| SCHEMBL12975615 | 0.88 | ALDH1A1 (0.51) | ALDH1A1F7F3MAPTCYP19A1 | |
| SCHEMBL23017141 | 0.88 | ALDH1A1 (0.44) | ALDH1A1F7F3MAPTCYP19A1 | |
| SCHEMBL931447 | 0.88 | ALDH1A1 (0.44) | ALDH1A1F7F3MAPTCYP19A1 | |
| SCHEMBL29073201 | 0.87 | LPAR2 (0.52) | LPAR2LPAR3LPAR1 | |
| SCHEMBL12474184 | 0.87 | ALDH1A1 (0.58) | ALDH1A1 | |
| SCHEMBL6261092 | 0.87 | ALDH1A1 (0.58) | ALDH1A1 | |
| SCHEMBL20548251 | 0.87 | LPAR2 (0.52) | LPAR2LPAR3LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 326 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117298034-A | Drug-loaded microemulsion-nanogel composite preparation for treating children eczema and preparation method and application thereof | 临沂大学 | 2023-12-29 | — | — | CN | claimed |
| CN-117379342-A | Solid powder cosmetic | 株式会社常盘 | 2024-01-12 | — | — | CN | disclosed |
| CN-117298034-A | Drug-loaded microemulsion-nanogel composite preparation for treating children eczema and preparation method and application thereof | 临沂大学 | 2023-12-29 | — | — | CN | disclosed |
| CN-111741741-B | Solid powder cosmetic | 株式会社常盘 | 2023-11-21 | — | — | CN | disclosed |
| US-11382884-B2 | Method for reducing lung infection | Respirion Pharmaceuticals Pty Ltd (CA) | 2022-07-12 | — | — | US | disclosed |
| EP-3641750-A1 | METHOD FOR REDUCING LUNG INFECTION | Respirion Pharmaceuticals Pty Ltd (AU) | 2020-04-29 | — | — | EP | disclosed |
| US-20200108033-A1 | METHOD FOR REDUCING LUNG INFECTION | Respirion Pharmaceuticals Pty Ltd (AU) | 2020-04-09 | — | — | US | disclosed |
| US-10561649-B2 | Pharmaceutical combination of opioid and prostaglandin compound | SUCAMPO AG (CH) | 2020-02-18 | — | — | US | disclosed |
| WO-2018232453-A1 | METHOD FOR REDUCING LUNG INFECTION | Respirion Pharmaceuticals Pty Ltd (AU) | 2018-12-27 | — | — | WO | disclosed |
| US-20180311233-A1 | PHARMACEUTICAL COMBINATION OF OPIOID AND PROSTAGLANDIN COMPOUND | SUCAMPO AG (CH) | 2018-11-01 | — | — | US | disclosed |
| US-20010056104-A1 | Treatment of ocular hypertension and glaucoma | SUCAMPO, A.G. (CH) | 2001-12-27 | — | — | US | disclosed |
| EP-0736591-B1 | Lubricating oil additive, lubricating oil and working fluid for refrigerators | JAPAN ENERGY CORP (JP) | 2001-12-12 | — | — | EP | disclosed |
| US-20010034355-A1 | Treatment of ocular hypertension | SUCAMPO, AG (CH) | 2001-10-25 | — | — | US | disclosed |
| WO-2001076593-A2 | BILE SECRETION PROMOTING COMPOSITION A 15-KETO PROSTAGLANDIN | SUCAMPO AG (CH) | 2001-10-18 | — | — | WO | disclosed |
| WO-2001068072-A2 | COMPOSITION FOR USE IN TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA | SUCAMPO AG (CH) | 2001-09-20 | — | — | WO | disclosed |
| WO-2001027099-A2 | BICYCLIC COMPOUNDS COMPOSITION AND METHOD FOR STABILIZING THE SAME | SUCAMPO, A.G. (CH) | 2001-04-19 | — | — | WO | disclosed |
| WO-2001005388-A2 | USE OF A FATTY DERIVATIVE FOR THE TREATMENT OF EXTERNAL SECRETIONDISORDERS | SUCAMPO, A.G. (CH) | 2001-01-25 | — | — | WO | disclosed |
| WO-2000077302-A1 | USE OF LONG-CHAIN FATTY ETHERS | NOPCO PAPER TECHNOLOGY HOLDING AS (NO) | 2000-12-21 | — | — | WO | disclosed |
| US-5744053-A | COMPRISING PARTIALLY ETHERIFIED POLYHYDRIC ALCOHOL AND PHOSPHATE COMPOUND | JAPAN ENERGY CORPORATION (JP) | 1998-04-28 | — | — | US | disclosed |
| EP-0736591-A2 | Lubricating oil additive, lubricating oil and working fluid for refrigerators | JAPAN ENERGY CORPORATION (JP) | 1996-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034355-A1 | Treatment of ocular hypertension | PTGIS, PTGIR, PTGS1 | ALDH1A1 216/4885F7 3341/4885F3 2267/4885 |
| US-20180311233-A1 | PHARMACEUTICAL COMBINATION OF OPIOID AND PROSTAGLANDIN COMPOUND | OPRK1, OPRM1, OPRD1 | ALDH1A1 498/4885F7 1534/4885F3 2771/4885 |
| US-10561649-B2 | Pharmaceutical combination of opioid and prostaglandin compound | OPRK1, OPRM1, OPRD1 | ALDH1A1 498/4885F7 1534/4885F3 2771/4885 |
| US-20010056104-A1 | Treatment of ocular hypertension and glaucoma | PTGIS, PTGIR, PTGS1 | ALDH1A1 422/4885F7 2498/4885F3 2406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.